Genovis AB (publ.) Asset Resilience Ratio
Genovis AB (publ.) asset resilience ratio. Genovis AB (publ.) (GENO) has an Asset Resilience Ratio of 43.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genovis AB (publ.) (GENO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genovis AB (publ.) (2013–2025)
Asset resilience ratio of Genovis AB (publ.) from 2013 to 2025. This chart shows how Genovis AB (publ.)'s Asset Resilience Ratio has changed over time. Read GENO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genovis AB (publ.)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Genovis AB (publ.).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr163.19 Million | 43.18% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr163.19 Million | 43.18% |
Asset Resilience Insights
- Very High Liquidity: Genovis AB (publ.) maintains exceptional liquid asset reserves at 43.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genovis AB (publ.) Industry Peers by Asset Resilience Ratio
Compare Genovis AB (publ.)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Genovis AB (publ.) Asset Resilience Ratio by Year (2013–2025)
Genovis AB (publ.) asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Genovis AB (publ.).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | Skr163.19 Million ≈ $17.56 Million |
Skr377.93 Million ≈ $40.67 Million |
-8.57pp |
| 2024-12-31 | 51.75% | Skr169.44 Million ≈ $18.23 Million |
Skr327.41 Million ≈ $35.23 Million |
+9.08pp |
| 2023-12-31 | 42.67% | Skr123.26 Million ≈ $13.26 Million |
Skr288.86 Million ≈ $31.09 Million |
-5.71pp |
| 2022-12-31 | 48.39% | Skr72.83 Million ≈ $7.84 Million |
Skr150.52 Million ≈ $16.20 Million |
-8.98pp |
| 2021-12-31 | 57.37% | Skr81.31 Million ≈ $8.75 Million |
Skr141.75 Million ≈ $15.25 Million |
+16.00pp |
| 2020-12-31 | 41.37% | Skr44.12 Million ≈ $4.75 Million |
Skr106.65 Million ≈ $11.48 Million |
+10.80pp |
| 2019-12-31 | 30.57% | Skr14.99 Million ≈ $1.61 Million |
Skr49.04 Million ≈ $5.28 Million |
+5.24pp |
| 2018-12-31 | 25.33% | Skr9.58 Million ≈ $1.03 Million |
Skr37.83 Million ≈ $4.07 Million |
+6.63pp |
| 2017-12-31 | 18.69% | Skr4.92 Million ≈ $529.22K |
Skr26.31 Million ≈ $2.83 Million |
-0.90pp |
| 2016-12-31 | 19.59% | Skr4.28 Million ≈ $460.74K |
Skr21.85 Million ≈ $2.35 Million |
-5.97pp |
| 2014-12-31 | 25.56% | Skr5.00 Million ≈ $538.08K |
Skr19.56 Million ≈ $2.11 Million |
+18.32pp |
| 2013-12-31 | 7.24% | Skr3.00 Million ≈ $322.85K |
Skr41.45 Million ≈ $4.46 Million |
-- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more